Wilh. Sonesson sells product rights in Germany through its Bioglan subsidiary

7/18/2002 8:39 AM EST

Wilh. Sonesson sells product rights in Germany through its Bioglan
subsidiary

Wilh. Sonesson AB acquired the pharma company Bioglan AB in Malmö on 13
May 2002.
In connection with the acquisition Bioglan sold its whole research
operation to a public English company.

As previously announced Bioglan gave the buyer an option to acquire
rights to marketed products, primarily in Germany. These products are
not of strategic importance since the geographic focus of Bioglan, as
well as all other Wilh. Sonesson operations, is the Nordic countries.

The option has been called on, and the buyer is Riemser Arzneimittel AG,
a German pharma company. Riemser has payed 52 MSEK for the product
rights, which of 20 MSEK is paid in cash and MSEK 32 by accepting
liabilities.

For the Wilh. Sonesson corporation the transaction has limited influence
on profit, and the net debt is reduced by 20 MSEK.

Lund 18 July 2002

Wilh. Sonesson AB (publ)

For further information please contact

Fredrik Lindgren, Vice President,
Tel. +46-46-280 81 00 or +46-705-616177